Molecular characterization of resistance to rifampicin in clinical isolates of Neisseria meningitidis  by Skoczynska, A. et al.
Acknowledgements
We thank B. Dragsten for performing the PFGE.
Transparency declaration
B. So¨derquist has served as a consultant to Pﬁzer AB,
Sweden.
References
1. Berglund C, Mo¨lling P, Sjo¨berg L, So¨derquist B. Predominance of
staphylococcal cassette chromosome mec (SCCmec) type IV
among methicillin-resistant Staphylococcus aureus (MRSA) in a
Swedish county and presence of unknown SCCmec types with
Panton–Valentine leukocidin genes. Clin Microbiol Infect 2005; 11:
447–456.
2. Berglund C, So¨derquist B. The origin of a methicillin-resistant
Staphylococcus aureus (MRSA) at a neonatal ward in Sweden—
possible horizontal transfer of a staphylococcal cassette chromo-
some mec between methicillin-resistant Staphylococcus haemolyticus
and Staphylococcus aureus. Clin Microbiol Infect 2008; 14: 1048–
1056.
3. Okuma K, Iwakawa K, Turnidge JD et al. Dissemination of new
methicillin-resistant Staphylococcus aureus clones in the community.
J Clin Microbiol 2002; 40: 4289–4294.
4. Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H,
Watanabe S. Identiﬁcation of methicillin-resistant strains of staphylo-
cocci by polymerase chain reaction. J Clin Microbiol 1991; 29: 2240–
2244.
5. Hussain Z, Stoakes L, Massey V et al. Correlation of oxacillin MIC
with mecA gene carriage in coagulase-negative staphylococci. J Clin
Microbiol 2000; 38: 752–754.
6. Swenson JM, Tenover FC. Cefoxitin disk study group. Results of disk
diffusion testing with cefoxitin correlate with presence of mecA in
Staphylococcus spp. J Clin Microbiol 2005; 43: 3818–3823.
7. Souza Antunes AL, Secchi C, Reiter KC, Rodrigues Perez LR, Peixoto
de Freitas AL, Alves d’Azevedo P. Evaluation of oxacillin and cefoxitin
disks for detection of resistance in coagulase negative staphylococci.
Mem Inst Oswaldo Cruz 2007; 102: 719–723.
8. Higashide M, Kuroda M, Ohkawa S, Ohta T. Evaluation of a cefoxitin
disk diffusion test for the detection of mecA-positive methicillin-resis-
tant Staphylococcus saprophyticus. Int J Antimicrob Agents 2006; 27: 500–
504.
9. Kahlmeter G. An international survey of the antimicrobial suscepti-
bility of pathogens from uncomplicated urinary tract infections: the
ECO.SENS project. J Antimicrob Chemother 2003; 51: 69–76.
10. Widerstro¨m M, Wistro¨m J, Ferry S, Karlsson C, Monsen T. Molecu-
lar epidemiology of Staphylococcus saprophyticus isolated from women
with uncomplicated community-acquired urinary tract infection. J Clin
Microbiol 2007; 45: 1561–1564.
11. Wisplinghoff H, Rosato AE, Enright MC, Noto M, Craig W, Archer
GL. Related clones containing SCCmec type IV predominate among
clinically signiﬁcant Staphylococcus epidermidis isolates. Antimicrob
Agents Chemother 2003; 47: 3574–3579.
12. Miragaia M, Couto I, de Lencastre H. Genetic diversity among methi-
cillin-resistant Staphylococcus epidermidis (MRSE). Microb Drug Resist
2005; 11: 83–93.
13. Mombach Pinheiro Machado AB, Reiter KC, Paiva RM, Barth AL. Dis-
tribution of staphylococcal cassette chromosome mec (SCCmec)
types I, II, III and IV in coagulase-negative staphylococci from patients
attending a tertiary hospital in southern Brazil. J Med Microbiol 2007;
56: 1328–1333.
14. Hanssen AM, Kjeldsen G, Sollid JU. Local variants of staphylococcal
cassette chromosome mec in sporadic methicillin-resistant Staphylo-
coccus aureus and methicillin-resistant coagulase-negative staphylo-
cocci: evidence of horizontal gene transfer? Antimicrob Agents
Chemother 2004; 48: 285–296.
15. Higashide M, Kuroda M, Omura CT et al. Methicillin-resistant Staphy-
lococcus saprophyticus carrying staphylococcal cassette chromosome
mec (SCCmec) have emerged in urogenital tract infections. Antimicrob
Agents Chemother 2008; 52: 2061–2068.
Molecular characterization of resistance to
rifampicin in clinical isolates of Neisseria
meningitidis
A. Skoczynska1,2, C. Ruckly1, E. Hong1 and M-K. Taha1
1) Neisseria Unit, Institute Pasteur, Paris, France and 2) National
Reference Centre for Bacterial Meningitis, National Medicines Institute,
Warsaw, Poland
Abstract
Among 3904 meningococcal isolates collected between October
2002 and June 2007 by the French Meningococcal Reference
Centre, eight (0.20%) were resistant to rifampicin (Rif-R;
MIC >1 mg/L) and 27 (0.69%) were intermediate-resistant to
rifampicin (Rif-I; MICs between 0.38 mg/L and 1 mg/L) according
to the E-test method. The MICs determined by agar dilution
were lower, eliminating the E-test intermediate category. All
Rif-R isolates had mutations in the rpoB gene, resulting in
substitutions at or near amino acid position 552, which were
absent in non-resistant isolates. These data suggest that a
rifampicin clinical breakpoint of 1.0 mg/L should be adopted for
Neisseria meningitidis.
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Rifampicin is one of the antibiotics of choice for
chemoprophylaxis of meningococcal disease, but its use may
be hindered by contraindications or by the emergence of
resistant strains [1–3]. However, the characterization of
rifampicin resistance in Neisseria meningitidis remains
problematic because there is no consensus concerning the
breakpoints. We aimed to characterize meningococcal
isolates with different rifampicin MIC values in order to
better deﬁne and characterize meningococcal resistance to
this antibiotic.
For the present study, we considered all isolates
(n = 3904) received by the French Meningococcal Reference
Centre between 15 October 2002 and 30 June 2007,
including 2812 invasive and 1092 non-invasive isolates. We
selected all isolates (n = 35) with rifampicin MICs >0.25 mg/
L as determined by the E-test method (AB Biodisk, Solna,
Sweden), which is the breakpoint value for this antibiotic
according to the Committee of the Antibiogram of the
French Society for Microbiology (http://www.sfm.asso.fr).
The isolates were further divided into two groups: (i) MICs
>1 mg/L, highly resistant to rifampicin (Rif-R; n = 8) and (ii)
MICs between 0.38 mg/L and 1 mg/L, intermediate-resistant
(Rif-I; n = 27). All Rif-R isolates and six Rif-I were invasive.
The Rif-R isolates seem to be very rare because they
account for only 0.28% of all invasive meningococci collected
during the study. Nineteen rifampicin-susceptible (Rif-S;
MIC £0.25 mg/L) invasive isolates were randomly chosen as
controls. Serotyping and characterization by multilocus
sequence typing (MLST) and porA typing revealed a heteroge-
neity of the selected isolates [4–6] (http://pubmlst.org, http://
neisseria.org) (Table 1).
High levels of resistance to rifampicin (MIC >32 mg/L)
correlated with point mutations in the rpoB gene encoding
the b subunit of RNA polymerase [2,3,7,8]. Therefore, a
fragment of the rpoB gene (encoding amino acids 435–644)
was ampliﬁed using primers as previously described [7]. All
Rif-R isolates (MIC >32 mg/L) belonged to serogroups B or
C and several sequence types. They showed mutations,
absent in non-resistant isolates, resulting in the substitutions
at or near position 552, which are known to confer
resistance to rifampicin (Table 1) [2,3,7,8]. The mutation
H552R was detected for the ﬁrst time in a clinical
meningococcal isolate. Previously, this has been reported
only in N. meningitidis and Escherichia coli mutants generated
in vitro and in clinical Mycobacterium tuberculosis isolates
[3,9,10].
Most of the Rif-R isolates (six of eight) in the present
study were detected after a previous round of
chemoprophylaxis with rifampicin, where the corresponding
index isolates were Rif-S according to phenotypic methods
and/or rpoB sequencing. It is noteworthy that four different
mutations were detected, suggesting independent events
occurring in the four Rif-R isolates belonging to the same
genetic lineage (the clonal complex ST-11).
One Rif-I isolate had mutation G560S, which did not
confer decreased susceptibility/resistance to rifampicin upon
transformation of a susceptible isolate with the appropriate
PCR products; however, a mutation in the corresponding
position has been reported previously in a rifampicin-resis-
tant strain of E. coli [10]. The other rpoB alterations that
were detected in Rif-S and Rif-I isolates may correspond to
polymorphic sites that characterize genes in N. meningitidis
[11].
Other mechanisms may be involved in resistance to
rifampicin [2,12,13]. In Neisseria gonorrhoeae, resistance to
diverse hydrophobic agents (including Triton X, rifampicin and
erythromycin) is associated with mutations in the mtrR gene
or its promoter region, encoding a transcriptional repressor
(MtrR) of the efﬂux pump genes for MtrCDE, found in both
pathogenic Neisseria spp. [12,14,15]. Agar dilution was used
according to the guidelines of the CLSI, in addition to the
E-test method, to test susceptibility to rifampicin (Sigma-
Aldrich Chemie), rifampicin with 0.05% Tween 80 (Merck),
Triton X (Merck), and erythromycin (Sigma-Aldrich Chemie)
[16]. All MICs of rifampicin for the Rif-I isolates, as determined
by the E-test method, were lower, ranging from <0.0037 to
0.25 mg/L by the agar dilution method.
MICs of rifampicin combined with 0.05% Tween 80 (added
to determine whether low permeability of the cell membrane
could be responsible for the higher MICs of rifampicin) were
generally the same as, or up to three dilutions lower than,
MICs of rifampicin [2]. There were no signiﬁcant differences
in the MICs of Triton X and erythromycin among the Rif-R,
Rif-I and Rif-S isolates (data not shown).
Next, a segment of the mtrR gene with its promoter
region was ampliﬁed using primers mtrF (5¢-gttttcccagtcac-
gacgttgtaTGCGGCTCGCCGCCTTGTCCTG-3¢) and mtrR
(5¢-ttgtgagcggataacaatttcGCTTGCGGGCAATGGCGATAAC
GG-3¢) with the universal adaptors (in lower case) added
for sequencing. Analysis of the sequence alignment suggested
no correlation between resistance to rifampicin and altera-
tions in the mtrR gene and its promoter in meningococcal
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isolates, as had been previously suggested [12,14,15].
However, further studies are required to explore other
molecular mechanisms of control of the mtrCDE-encoded
efﬂux pump.
The rifampicin breakpoints established by the EUCAST
and the CLSI differ (http://www.srga.org/eucastwt/MICTAB/
MICmiscellaneous.html) [16]. In addition, a wide range of
breakpoints, in the range 0.25–5 mg/L, is used by
laboratories that are members of the European Monitoring
Group of Meningococci [17]; see also M. K. Taha
(unpublished data). During a recent multicentre study,
rifampicin was one of the antibiotics for which agreement
between the E-test and the agar dilution method, and among
laboratories, was the weakest [18]. The data obtained in the
present study suggest that the Rif-I and Rif-S isolates,
differentiated by the E-test method, may represent a single
group. Consequently, we suggest the clinical breakpoint of
1.0 mg/L for rifampicin in N. meningitidis for both the agar
dilution and E-test method [16]. This MIC is lower than the
concentration of 5.3 mg/L reached by rifampicin in epithelial
lining ﬂuid 2–5 h after a single dose of 600 mg [19]. The
proposed value differs from the EUCAST clinical breakpoint
TABLE 1. Characteristics of and results for Neisseria meningitidis isolates used in the present study
Isolate Year Source Phenotype ST CC Rif E-test Rif AD Rif+ T80 RpoB MtrR
20427 2003 RT NG:15:P1.6 1136 NA 0.38 0.25 0.12 –a Y48H
20500 2003 RT NG:15:P1.6 1136 NA 0.38 0.12 0.06 – wt
20605 2003 Blood C:2a:P1.5,2 11 11 0.38 0.12 0.06 – D79-81
20642 2003 RT C:NT:NST 1031 334 0.38 0.25 0.25 – Stop 54
20704 2003 RT NG:1:P1.12 6119 NA 0.38 0.25 0.12 – No PCR product
20782 2003 RT NG:15:P1.6 1136 NA 0.38 0.25 0.12 – wt
20796 2003 Blood B:NT:P1.9 571 41/44 0.5 0.0075 £0.0037 – A77T
20938 2003 RT NG:NT:P1.7 53 53 0.38 0.12 0.12 – A77T
21221 2003 Urethra NG:15:P1.6 1136 NA 0.38 0.06 0.06 – M1L
21696 2004 Rectum NG:15:P1.6 1136 NA 0.38 0.12 0.06 – wt
21788 2004 RT NG:15:P1.6 6095 NA 0.38 0.06 0.03 – wt
21814 2004 RT NG:15:P1.6 1136 NA 0.38 0.12 0.12 – wt
22092 2004 RT X:15:P1.6 1136 NA 0.38 0.06 0.03 – wt
22107 2004 RT X:15:NST 1136 NA 0.5 0.25 0.12 – Stop 114
22137 2004 RT W135:NT:NST 184 22 1 0.25 0.12 – Stop 85
22167 2005 CSF B:NT:P1.4 41 41/44 0.5 0.25 0.25 G560S wt
22179 2005 RT NG:15:P1.6 1136 NA 0.38 0.25 0.12 – wt
22290 2005 RT NG:15:P1.6 198 198 0.5 0.12 0.12 – A77T
22399 2005 RT NG:15:P1.6 1136 NA 0.5 0.25 0.12 – wt
22578 2005 RT NG:15:P1.6 1136 NA 0.38 0.06 0.03 – wt
22676 2005 RT NG:NT:NST 571 41/44 0.38 0.12 0.12 – A77T
22703 2005 RT NG:15:P1.7 2154 NA 0.38 0.12 0.12 – No PCR product
22740 2005 Rectum NG:NT:P1.6 6120 NA 0.5 0.12 0.12 – A29V
22750 2005 CSF C:2a:P1.5 11 11 0.38 0.015 0.015 – wt
22751 2005 Blood C:2a:P1.5 11 11 0.38 0.015 0.015 – wt
23616 2006 Blood A:4:NST 7 5 0.38 0.12 0.12 – wtb
23859 2007 RT NG:15:P1.6 6096 NA 0.5 0.12 0.12 – Stop 106
20957 2003 CSF C:2a:P1.5 11 11 >32 512 256 S557F wt
22093 2004 Blood B:NT:NST 749 32 >32 64 64 H552N F51C
22330 2005 CSF B:14:P1.7,16 32 32 >32 1024 256 H552Y wt
22342 2005 CSF B:14:P1.7,16 32 32 >32 1024 256 H552Y wt
22637 2005 Blood C:2a:P1.5,2 11 11 >32 >1024 256 H552R wt
23001 2005 CSF B:NT:P1.4 6005 41/44 >32 512 256 H552Y wt
23269 2006 Blood C:NT:P1.5,2 11 11 >32 256 32 H552Y G45D
24089 2007 Blood C:2a:P1.1,7 6048 11 >32 256 256 S548F wt
21335 2004 Blood B:4:P1.10 6094 41/44 0.012 £0.0037 0.0075 – wt
23026 2006 Blood C:NT:P1.5,2 11 11 0.008 £0.0037 £0.0037 – wt
23036 2006 Blood E29:NT:P1.2 60 60 0.008 £0.0037 0.0075 – wt
23047 2006 CSF B:4:P1.10 32 32 0.006 £0.0037 £0.0037 – wt
23051 2006 CSF B:1:NST 1946 461 0.032 £0.0037 0.03 – A29T
23100 2006 Blood B:1:NST 207 41/44 0.008 £0.0037 0.0075 – L47R
23135 2006 CSF A:4:P1.9 4789 5 0.064 0.03 0.06 – A77T
23142 2006 CSF Y:14:NST 23 23 0.003 £0.0037 £0.0037 – wt
23198 2006 Blood W135:NT:NST 22 22 0.008 £0.0037 0.0075 – wt
23248 2006 Blood B:2b:NST 8 8 0.008 £0.0037 £0.0037 – E78K, G83E, A86T
23280 2006 blood B:14:P1.7,16 32 32 0.008 0.015 0.06 – wt
23318 2006 CSF B:15:NST 6359 41/44 0.012 £0.0037 0.0075 – wt
23324 2006 Blood C:2a:P1.5,2 1026 11 0.008 £0.0037 0.0075 – wt
23343 2006 CSF C:2b:P1.5,2 8 8 0.023 0.015 0.06 – E78K, G83E, A86T
23352 2006 Blood B:14:NST 492 269 0.008 £0.0037 0.0075 – wt
23390 2006 CSF B:NT:P1.9 6122 NA 0.032 £0.0037 0.0075 – E78K, G83E, A86T
23396 2006 CSF B:NT:P1.13 6121 NA 0.012 £0.0037 0.0075 – wt
23441 2006 Blood NG:15:P1.6 823 198 0.032 0.0075 0.015 – A77T
23575 2006 CSF B:1:P1.6 6360 461 0.125 0.06 0.06 – A29T
RT, respiratory tract; CSF, cerebrospinal ﬂuid; NG, non-groupable isolate; NT, non-typeable isolate; NST, non-subtypeable isolate; ST, sequence type; CC, clonal complex;
NA, not assigned to a known clonal complex; Rif, rifampicin MIC (mg/L); AD, agar dilution; Rif+T80, rifampicin MIC in the presence of Tween80 (mg/L).
aNo mutations around the position 552; wt, wild-type sequence found as the most common sequence present among Rif-susceptible isolates.
bIsolate with G to A transition within the mtrR promoter region.
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(0.25 mg/L), which appears to be too low for the E-test
method routinely employed in many laboratories. It is
necessary to emphasize that the efﬁcacy of eradication is not
100%, and that chemoprophylaxis failures were reported
even for fully susceptible isolates [20].
The suggested breakpoint should now be challenged using
a large collection of varied meningococcal isolates from
different countries spanning many years.
Acknowledgements
We thank J.-M. Alonso for generous support for this project
and S. Murchan for editing the English language. Some data
included in the paper were presented as an oral presentation
at the 9th European Monitoring Group on Meningococci
(EMGM) Meeting, Rome, 30 May to 1 June 2007.
Transparency Declaration
A. Skoczynska was supported by a Marie Curie Intra-Euro-
pean Fellowship (No. 23188) within the Sixth European
Community Framework Programme. All authors: no conﬂict
of interest.
References
1. Yagupsky P, Ashkenazi S, Block C. Rifampicin-resistant meningococci
causing invasive disease and failure of chemoprophylaxis. Lancet 1993;
341: 1152–1153.
2. Abadi FJ, Carter PE, Cash P, Pennington TH. Rifampin resistance in
Neisseria meningitidis due to alterations in membrane permeability.
Antimicrob Agents Chemother 1996; 40: 646–651.
3. Carter PE, Abadi FJ, Yakubu DE, Pennington TH. Molecular
characterization of rifampin-resistant Neisseria meningitidis. Antimicrob
Agents Chemother 1994; 38: 1256–1261.
4. Abdillahi H, Poolman JT. Neisseria meningitidis group B serosubtyping
using monoclonal antibodies in whole-cell ELISA. Microb Pathog 1988;
4: 27–32.
5. Fox AJ, Taha MK, Vogel U. Standardized nonculture techniques rec-
ommended for European reference laboratories. FEMS Microbiol Rev
2007; 31: 84–88.
6. Maiden MC, Bygraves JA, Feil E et al. Multilocus sequence typing: a
portable approach to the identiﬁcation of clones within populations
of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95:
3140–3145.
7. Taha MK, Zarantonelli ML, Ruckly C, Giorgini D, Alonso JM.
Rifampin-resistant Neisseria meningitidis. Emerg Infect Dis 2006; 12:
859–860.
8. Nolte O, Muller M, Reitz S, Ledig S, Ehrhard I, Sonntag HG.
Description of new mutations in the rpoB gene in rifampicin-resistant
Neisseria meningitidis selected in vitro in a stepwise manner. J Med
Microbiol 2003; 52: 1077–1081.
9. Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-
resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:
647–650.
10. Severinov K, Soushko M, Goldfarb A, Nikiforov V. Rifampicin region
revisited. New rifampicin-resistant and streptolydigin-resistant
mutants in the beta subunit of Escherichia coli RNA polymerase.
J Biol Chem 1993; 268: 14820–14825.
11. Maiden MC. Population genetics of a transformable bacterium: the
inﬂuence of horizontal genetic exchange on the biology of Neisseria
meningitidis. FEMS Microbiol Lett 1993; 112: 243–250.
12. Pan W, Spratt BG. Regulation of the permeability of the gonococcal
cell envelope by the mtr system. Mol Microbiol 1994; 11: 769–775.
13. Hui J, Gordon N, Kajioka R. Permeability barrier to rifampin in myco-
bacteria. Antimicrob Agents Chemother 1977; 11: 773–779.
14. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM.
Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic
agents is modulated by the mtrRCDE efﬂux system. Microbiology
1995; 141: 611–622.
15. Rouquette-Loughlin CE, Balthazar JT, Hill SA, Shafer WM. Modulation
of the mtrCDE-encoded efﬂux pump gene complex of Neisseria men-
ingitidis due to a Correia element insertion sequence. Mol Microbiol
2004; 54: 731–741.
16. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing; ﬁfteenth informational supplement. CLSI
document M100-S15. Wayne, PA: CLSI, 2005.
17. Block C. Antibiotic susceptibility testing. In: Pollard AJ, Maiden MCJ,
eds, Meningococcal disease. Methods and protocols. Totowa, NJ:
Humana Press, Inc., 2001; 89–106.
18. Vazquez JA, Arreaza L, Block C et al. Interlaboratory comparison of
agar dilution and Etest methods for determining the MICs of
antibiotics used in management of Neisseria meningitidis infections.
Antimicrob Agents Chemother 2003; 47: 3430–3434.
19. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. Rifampicin
concentrations in bronchial mucosa, epithelial lining ﬂuid, alveolar
macrophages and serum following a single 600 mg oral dose in
patients undergoing ﬁbre-optic bronchoscopy. J Antimicrob Chemother
2002; 50: 1011–1015.
20. Tsakris A, Trakatelli C, Souliou E, Soﬁanou D, Ntoutsou K,
Antoniadis A. Failures of rifampicin and ciproﬂoxacin to eradicate a
susceptible meningococcal isolate from a close contact of a fatal case.
Infection 2001; 29: 293–294.
CMI Research Notes 1181
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1170–1191
